Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

@article{Jann2002ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors},
  author={Michael W. Jann and Kara Lee Shirley and Gary W. Small},
  journal={Clinical Pharmacokinetics},
  year={2002},
  volume={41},
  pages={719-739}
}
Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer’s disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity.Tacrine was the first cholinesterase inhibitor approved by regulatory agencies, followed by donepezil, rivastigmine and recently galantamine. With the exception of low doses of tacrine, the cholinesterase inhibitors exhibit a linear relationship between dose and area under the plasma… 
Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease
TLDR
The aim of this review is to summarize the pharmacodynamics and pharmacokinetics of the four commonly used anti-dementia drugs and to give an overview on the current knowledge of pharmacogenetics in this field.
Clinically Significant Drug Interactions with Cholinesterase Inhibitors
TLDR
A review of the literature does not reveal any alarming data but does highlight the need for prudent prescription, particularly when cholinesterase inhibitors are given in combination with psychotropics or antiarrhythmics.
Pharmacokinetic rationale for the rivastigmine patch
TLDR
The potential of a patch to improve the tolerability of rivastigmine while permitting similar exposure to the highest doses of capsules may, in turn, lead to improved efficacy and compliance.
Pharmacokinetic and Pharmacodynamic Properties of Cholinesterase Inhibitors Donepezil, Tacrine, and Galantamine in Aged and Young Lister Hooded Rats
TLDR
Greater age effects in both pharmacokinetics and pharmacodynamics of donepezil and tacrine were seen in previous studies with Fischer 344 rats, indicating a potential risk in overreliance on this rat strain for aging studies.
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease
  • R. Cacabelos
  • Medicine
    Expert opinion on drug metabolism & toxicology
  • 2020
TLDR
The most relevant genes influencing AChEI efficacy and safety are APOE and CYPs, and APOE-4 carriers are the worst responders to A ChEIs.
Donepezil: a review
  • B. Seltzer
  • Medicine
    Expert opinion on drug metabolism & toxicology
  • 2005
TLDR
Although donepezil was originally developed to inhibit the breakdown of the neurotransmitter acetylcholine as symptomatic therapy for AD, recent studies raise the possibility of other effects this drug has on the pathogenesis of AD.
Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition?
  • D. Moss
  • Medicine
    Journal of Alzheimer's disease : JAD
  • 2019
TLDR
The co-administration of an anticholinergic with an AChE inhibitor is a rational strategy for improving efficacy in the symptomatic treatment of dementia, but there are significant long-term risks that have not yet been considered.
The Inhibitory Effect of Rivastigmine and Galantamine on Choline Transport in Brain Capillary Endothelial Cells
【The blood-brain barrier (BBB) transport of acetylcholinesterase (AChE) inhibitors, donepezil and tacrine suggested to be mediated by choline transport system in our previous study. Therefore, in the
Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease.
TLDR
Plasma concentrations of S-donepezil (based on CYP2D6 polymorphisms) were significantly associated with therapeutic responses, suggesting that plasma concentrations of donepezil influence therapeutic outcomes following treatment with didpezil in Han Chinese patients with Alzheimer's disease.
BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors
TLDR
Individualized therapy based on CYP2D6 and BCHE genotypes is unlikely to be beneficial for treating Alzheimer’s disease patients in routine clinical practice.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
Pharmacokinetic studies of cholinesterase inhibitors
The pharmacokinetic of some centrally acting cholinesterase inhibitors that have been used to improve memory in patients with dementia of Alzheimer's type, was compared. The original compound in this
Clinical Pharmacokinetics of Drugs for Alzheimer’s Disease
TLDR
The pharmacokinetics of nimodipine during multiple-dose treatment have not been studied extensively; however, the drug does not appear to accumulate during repeated administration of standard doses, and pharmacokinetic data should be determined when these methods of drug delivery are being assessed in clinical trials.
Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
TLDR
Tacrine is associated with hepatotoxicity while other cholinesterase inhibitors seem devoid this adverse effect, and concomitant medication with various drugs with rivastigmine does not seem to cause any drug interactions in patients with Alzheimer’s disease.
Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer’s Disease
TLDR
In conclusion, cholinesterase inhibitors are the only pharmacological agents proved to be effective for the treatment of Alzheimer’s disease in large, long term, double-blind, placebo-controlled trials.
Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease
  • M. Jann
  • Medicine
    Pharmacotherapy
  • 2000
TLDR
In the two large multicenter clinical trials that used a forced‐dosage titration scheme, rivastigmine 6–12 mg/day was superior to placebo on three cognitive and functioning scales (p<0.001).
Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses
Aim The aim of this study was to characterize the pharmacokinetic and pharmacodynamic profile of donepezil HCl, a chemically distinct and specific acetylcholinesterase (AChE) inhibitor for the
Donepezil Use in Alzheimer Disease
TLDR
Donepezil is an effective symptomatic treatment for some patients with mild-to-moderate Alzheimer disease and appears to be a safe alternative for tacrine, given its convenient once-daily dosing, minimal adverse effects, and lower total cost.
Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
  • E. Shintani, K. M. Uchida
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1997
TLDR
Donepezil appears to be preferable to tacrine as the initial agent for patients with mild to moderate dementia associated with Alzheimer's disease, with significant improvements in Alzheimer's Disease Assessment Scale-cognitive subscale and Clinical Interview-Based Impression of Change scores.
Clinical Pharmacokinetics of Tacrine
TLDR
It has been postulated that the elevated levels of transaminase associated with tacrine therapy in vivo are dependent upon bioactivation of tacrine, mediated by hepatic CYP1A2, to form a toxic compound.
Invited Review Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications
TLDR
Clinical results of four second generation cholinesterase inhibitors (ChEI) (donepezil, ENA 713, eptastigmine and metrifonate) are reviewed and compared and compared with other ChEI such as tacrine, physostIGmine and galanthamine and indicate that optimization of effects prolongation and maintenance of clinical gains will depend on further knowledge of the compounds pharmacodynamic properties.
...
1
2
3
4
5
...